Eli Lilly’s experimental obesity pill, orforglipron, met its main goals in a closely watched late-stage trial, boosting the company’s standing in the fast-growing market for weight loss and diabetes treatments. The results, announced Thursday, show the pill could offer a compelling, needle-free alternative to popular injections, potentially reshaping how millions…
The S&P 500 and Nasdaq Composite opened higher on Thursday, the final trading day of the week.The Dow Jones…
Hertz Global Holdings Inc (NASDAQ: HTZ) is up nearly 50% in premarket on Thursday after billionaire investor Bill Ackman…
The Nikkei 225 index has bounced back this month as the US and Japan continued their negotiations on tariffs.…
The FTSE 100 and FTSE 250 indices have rebounded over the past two weeks as European stocks have emerged…
GE Aerospace’s stock price is under pressure in 2025 as last year’s rally takes a breather and as investors…
The ServiceNow stock price has declined significantly over the past few months, dropping from a high of $1,196 in…
The S&P 500 index has declined significantly over the past few months, forming a death cross pattern for the…
Shareholders of LVMH Moët Hennessy Louis Vuitton voted on Thursday to allow Bernard Arnault to remain at the helm…